Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma

Johanna Chiffelle1, David Barras1, Rémy Pétremand1

  • 1Ludwig Institute for Cancer Research, Lausanne Branch, Department of Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Agora Cancer Research Center, Lausanne, Switzerland; Center for Cell Therapy, CHUV-Ludwig Institute, Lausanne, Switzerland.

Immunity
|September 14, 2024
PubMed

Insights

Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) shows variable results. Responders had more tumor-reactive TILs initially, which were better expanded and infiltrated tumors post-therapy, unlike non-responders.

Area of Science:

  • Immunology
  • Oncology
  • Cell Therapy

Background:

  • Adoptive cell therapy (ACT) using in vitro expanded tumor-infiltrating lymphocytes (TILs) shows inconsistent clinical responses in melanoma patients.
  • Understanding the factors driving therapeutic success is crucial for optimizing TIL-ACT.

Purpose of the Study:

  • To investigate the clonal dynamics of TILs from baseline tumors to post-ACT samples.
  • To identify characteristics of TIL clonotypes associated with clinical response to TIL-ACT in melanoma.

Main Methods:

  • Single-cell RNA and T cell receptor (TCR) sequencing were employed to track TIL clonotypes.
  • Analysis of baseline tumors, ACT products, and post-ACT blood and tumor samples from melanoma patients.

Main Results:

  • Clinical responders had baseline tumors enriched in tumor-reactive TILs, which were effectively expanded and led to tumor-specific CD8+ cell infiltration post-ACT.
  • Non-responders' tumors lacked tumor-reactive TILs, and their cell products were dominated by blood-borne clonotypes persisting in blood but not tumors.
  • Tumor-specific TILs lost exhaustion signatures upon expansion, with responders showing an intermediate exhausted effector state post-engraftment, suggesting functional reinvigoration.

Conclusions:

  • Tumor-reactive TIL clonotype dynamics are critical for clinical response to TIL-ACT.
  • Identifying and expanding tumor-specific TILs may improve TIL-ACT efficacy.
  • Findings offer insights for optimizing TIL-ACT strategies in melanoma.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
688
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
859
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K